HMG-CoA reductase inhibitor therapy and the risk of venous thromboembolism in joint replacement surgery

Article Type
Changed
Tue, 10/02/2018 - 11:04
Display Headline
HMG-CoA reductase inhibitor therapy and the risk of venous thromboembolism in joint replacement surgery
Article PDF
Author and Disclosure Information

William Ho, MBBS
St. Vincent’s Hospital, Melbourne, Victoria, Australia

Brendan Flaim, MBBS, FRACP
St. Vincent’s Hospital, Melbourne, Victoria, Australia

Andrea Chan, MBBS, FRACP
St. Vincent’s Hospital, Melbourne, Victoria, Australia

Publications
Page Number
eS16
Author and Disclosure Information

William Ho, MBBS
St. Vincent’s Hospital, Melbourne, Victoria, Australia

Brendan Flaim, MBBS, FRACP
St. Vincent’s Hospital, Melbourne, Victoria, Australia

Andrea Chan, MBBS, FRACP
St. Vincent’s Hospital, Melbourne, Victoria, Australia

Author and Disclosure Information

William Ho, MBBS
St. Vincent’s Hospital, Melbourne, Victoria, Australia

Brendan Flaim, MBBS, FRACP
St. Vincent’s Hospital, Melbourne, Victoria, Australia

Andrea Chan, MBBS, FRACP
St. Vincent’s Hospital, Melbourne, Victoria, Australia

Article PDF
Article PDF
Page Number
eS16
Page Number
eS16
Publications
Publications
Article Type
Display Headline
HMG-CoA reductase inhibitor therapy and the risk of venous thromboembolism in joint replacement surgery
Display Headline
HMG-CoA reductase inhibitor therapy and the risk of venous thromboembolism in joint replacement surgery
Citation Override
Cleveland Clinic Journal of Medicine 2010 March;77(e-suppl 1):eS16
Disallow All Ads
Alternative CME
Use ProPublica
Article PDF Media